Historical Trends and an International Vaccination Policy Comparison

Prepared October 2026 — ConsultJY Research Brief

Executive Summary

Before the chickenpox (varicella) vaccine was introduced in the United States in 1995, the disease caused roughly 4 million infections, 11,000 hospitalizations, and up to 150 deaths every year. A single-dose vaccination program cut that burden dramatically — but it took a second recommended dose, added in 2006, to bring the country to today’s levels of control.

The international record makes one thing especially clear: vaccination coverage alone does not predict outcomes. What matters most is whether a country uses a one-dose or two-dose schedule. South Korea reached outstanding one-dose coverage (95–97%+) yet saw reported cases rise for over a decade. Japan, starting from a two-dose schedule at roughly 90% coverage, cut incidence by 80% within five years. The United States already has the right program design — the real risk today is eroding execution, as coverage slips and exemptions rise in a growing number of states.

United States: The Historical Trajectory

The introduction of the varicella vaccine marks one of the more dramatic declines in a childhood disease’s burden in recent US public health history.

Period	Annual hospitalizations (approx.)	Context
Pre-1995 (pre-vaccine)	~11,000	~4 million cases/year nationally; up to 150 deaths/year
2012 (1-dose era)	~770	93% decline in hospitalizations vs. pre-vaccine baseline
2012–2015 (2-dose era)	Further decline	Additional ~38–40% drop in hospitalizations vs. the 1-dose period alone

By 2012, outpatient visits for varicella had fallen 84% and hospitalizations 93% compared to the pre-vaccine era — with the largest gains concentrated in children and teens, the group targeted by the vaccination program.

Where US Coverage Stands Today

For the 2025–2026 school year, national kindergarten coverage was:

• 93.4% — at least one dose of varicella vaccine
• 92.2% — completed two-dose series
• 92.3% — considered fully up to date (including documented disease history)

Warning sign: national coverage declined slightly compared to the prior year, with more than half of US states reporting drops in MMR, DTaP, polio, and varicella coverage — and vaccine exemptions rising at the same time.

State-level variation is substantial. Connecticut leads at 98.4% coverage; Idaho sits at just 74.6%, well below the roughly 90% threshold generally considered necessary to sustain herd immunity against a highly contagious disease like varicella.

International Comparison

Vaccination coverage percentage, on its own, is a poor predictor of outcomes. Dose schedule is the variable that actually separates success stories from cautionary ones.

Country	Program start	Dose schedule	Coverage	Outcome
United States	1995 (1-dose); 2006 (2-dose added)	Two-dose	~92%	93% fewer hospitalizations; further gains after 2nd dose added
Japan	2014	Two-dose from the start	~90%	80% reduction in incidence by 2019
South Korea	2005	One-dose only	95–97%+	Reported cases rose from ~11,000 (2006) to ~80,000 (2017) despite high coverage
Germany	2004 (1-dose); 2009 (2-dose added)	Two-dose (since 2009)	89% (dose 1) / 85% (dose 2)	Further reductions in hospitalizations after 2nd dose added
United Kingdom	Not adopted	No routine program (selective only)	N/A	61,024 varicella-related hospital admissions, 2004–2017; 38% involved a complication

Japan — The Clear Success Story

Japan delayed adopting routine vaccination until 2014 — decades after the US — but went straight to a two-dose schedule at roughly 90% coverage. The result was an 80% reduction in incidence within five years. One notable side effect: infection rates among teenagers (ages 10–14) rose after 2014, as the pool of older, unvaccinated individuals created a temporary shift in the age distribution of cases. This is a planning consideration, not a failure of the program.

South Korea — A Genuine Cautionary Tale

Korea added varicella to its National Immunization Program in 2005 using a single dose only, and achieved excellent coverage — consistently above 95%, reaching 97%+ by 2010. Despite this, reported cases rose substantially, from about 11,000 in 2006 to over 80,000 by 2017. Researchers attribute part of this increase to improved disease reporting rather than a true rise in infections, but the consensus is unambiguous: one-dose vaccination was “moderately effective” but “insufficient to interrupt varicella transmission,” and Korean researchers have explicitly called for a shift to a two-dose strategy.

Germany — Validates the Same Pattern Internally

Germany’s own before-and-after data tells the same story as the US/Korea/Japan comparison, within a single country. Germany began with a one-dose program in 2004, then added a second dose in 2009 specifically because of continued virus circulation and breakthrough infections. Each additional dose produced further, measurable reductions in hospitalizations.

United Kingdom and Much of Europe — No Program At All

The UK deliberately chose not to adopt universal varicella vaccination, based on a theory that childhood vaccination might reduce a protective “boosting” effect that helps adults’ immune systems suppress shingles (herpes zoster) later in life. The cost has been substantial: 61,024 varicella-related hospital admissions between 2004 and 2017, with 38% involving a recognized complication. The UK is now actively reconsidering this policy, as the shingles increase the theory predicted has not clearly materialized in countries that did vaccinate.

France, Ireland, the Netherlands, Denmark, and several other European countries similarly have no routine varicella recommendation, largely citing the same reasoning. By contrast, Finland, Greece, Italy, Latvia, Spain, and Hungary all run two-dose universal programs with coverage ranging from 83% to 97%.

The Core Insight for Prevention Policy

The strongest evidence-based argument is not simply “vaccinate vs. don’t.” It is: one dose is not enough. High single-dose coverage (Korea) still allows the disease to circulate at the population level. Two-dose programs (Japan, Germany, the US since 2006) are what actually drive transmission down.

The United States already has the right program design in place. The real and growing risk is not a flawed strategy — it is eroding execution: state-level coverage gaps and rising exemption rates arriving at the same time nationally. A prevention proposal built on this evidence should prioritize:

• Closing state-level coverage gaps, particularly in states falling meaningfully below the ~90% herd-immunity threshold (e.g., Idaho)
• Addressing the root causes of rising exemption rates before they compound further
• Protecting and reinforcing the existing two-dose schedule rather than treating it as a solved problem
• Monitoring for the age-shift effect seen in Japan, to ensure any coverage gains don’t simply shift disease burden to older, unvaccinated cohorts

Sources: U.S. CDC (MMWR, SchoolVaxView); peer-reviewed epidemiological studies (South Korea, Japan, Germany, Italy); UK NHS/PMC hospital admissions data; ECDC country-level vaccination policy survey.